Palo Alto Networks, Inc. (PANW) Unveils Seven AI-Driven Cybersecurity Predictions for 2025
We recently compiled a list of the 10 AI News Making Waves Today. In this article, we are going to take a look at where Palo ...
Hosted on MSN22h
Mystery Palo Alto Networks hijack-my-firewall zero-day now officially under exploit
Yank access to management interface, stat A critical zero-day vulnerability in Palo Alto Networks' firewall management ...
HHS1d
Palo Alto Reports Firewalls Exploited Using an Unknown Flaw
Attackers are exploiting a zero-day vulnerability in some types of Palo Alto Networks firewalls, the cybersecurity giant ...
Infosecurity-magazine.com1d
Palo Alto Networks Confirms New Zero-Day Being Exploited by Threat Actors
The security provider has elevated its warning about a vulnerability affecting firewall management interfaces after observing ...
Palo Alto Networks warns of critical RCE zero-day exploited in attacks
Palo Alto Networks is warning that a critical zero-day vulnerability on Next-Generation Firewalls (NGFW) management ...
Palo Alto Networks price target raised to $440 from $385 at Stifel
Stifel raised the firm’s price target on Palo Alto Networks (PANW) to $440 from $385 and keeps a Buy rating on the shares ahead of the ...
A critical Palo Alto Networks bug is being hit by cyberattacks, so patch now
A critical bug found in Palo Alto Networks’ Expedition program is being abused in the wild, the US government has warned. The ...
Palo Alto Daily Post24d
3 immigrant parents seek spots on high school board
Levich is a board member for Bowman School, a private school in Palo Alto. She said she wants to promote dual enrollment and vocational training that will attract more students to the district and ...
Seeking Alpha24d
Alto Neuroscience stock crashes amid failed study and Wedbush downgrade
Alto Neuroscience (NYSE:ANRO) shares nosedived 66% Wednesday morning, the first trading session, after the company announced its psychiatric drug ALTO-100 had failed a key clinical study. After ...
FierceBiotech24d
Alto's midphase depression trial falls flat, raising doubts about pitch to disrupt neuropsychiatry R&D
Alto Neuroscience hit a bum note in an early test of its precision neuropsychiatry model. A phase 2b trial of Alto’s lead drug candidate in depression missed its primary and key secondary ...
Yahoo Finance25d
Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder
Strong cash position expected to fund Alto’s planned operations through multiple near-term milestones across pipeline of independent programs – MOUNTAIN VIEW, Calif., October 22, 2024 ...